Cargando…

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

Detalles Bibliográficos
Autores principales:	Treon, Steven P., Castillo, Jorge J., Skarbnik, Alan P., Soumerai, Jacob D., Ghobrial, Irene M., Guerrera, Maria Luisa, Meid, Kirsten, Yang, Guang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2020
Materias:	Letter to Blood
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243149/ https://www.ncbi.nlm.nih.gov/pubmed/32302379 http://dx.doi.org/10.1182/blood.2020006288

Ejemplares similares

The race to stymie BTK: zanu zings
por: Kapoor, Prashant, et al.
Publicado: (2020)

Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia
por: Treon, Steven P., et al.
Publicado: (2021)

A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
por: Castillo, Jorge J., et al.
Publicado: (2022)

Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders
por: Thompson, Philip A., et al.
Publicado: (2023)

Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy
por: Gustine, Joshua N., et al.
Publicado: (2021)

Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials
por: Castillo, Jorge J., et al.
Publicado: (2020)

Ibrutinib and novel BTK inhibitors in clinical development
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy
por: Castillo, Jorge J., et al.
Publicado: (2022)

Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2021)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
por: Liu, Jia, et al.
Publicado: (2022)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
por: Nicolson, Phillip L.R., et al.
Publicado: (2018)

Ibrutinib directly reduces CD8+T cell exhaustion independent of BTK
por: Li, Ling, et al.
Publicado: (2023)

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
por: Sharma, Shruti, et al.
Publicado: (2016)

Controlling Ibrutinib’s Conformations about Its Heterobiaryl Axis to Increase BTK Selectivity
por: Toenjes, Sean T., et al.
Publicado: (2023)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells
por: Natarajan, Gayathri, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
por: Zhu, Zhen, et al.
Publicado: (2020)

Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia
por: de Porto, Alexander P., et al.
Publicado: (2019)

Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
por: Zucha, Muhammad Ary, et al.
Publicado: (2015)

Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice
por: Schutt, Steven D., et al.
Publicado: (2015)

Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis
por: Colado, Ana, et al.
Publicado: (2018)

Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
por: Zhu, Sining, et al.
Publicado: (2021)

Ibrutinib facilitates the sensitivity of colorectal cancer cells to ferroptosis through BTK/NRF2 pathway
por: Zhu, Jin-Feng, et al.
Publicado: (2023)

COVID-19–induced atypical pulmonary lymphocytes
por: Vergé, Véronique, et al.
Publicado: (2020)

Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib
por: Guo, Ailin, et al.
Publicado: (2015)

Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers
por: Yang, Xuedong, et al.
Publicado: (2019)

Ibrutinib Prevents Acute Lung Injury via Multi-Targeting BTK, FLT3 and EGFR in Mice
por: Rao, Huanan, et al.
Publicado: (2022)

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022)

Neutrophil-specific depletion of gasdermin D does not protect against murine sepsis
por: Liu, Fei, et al.
Publicado: (2023)

Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood. 2020;135(21):1912–1915.
Publicado: (2021)

Plasmavigilance—Adverse events among US Source plasma donors
por: Schreiber, George B., et al.
Publicado: (2021)

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
por: Zhu, Sining, et al.
Publicado: (2021)

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
por: Roeker, Lindsey E., et al.
Publicado: (2021)

A robust autonomous method for blood demand forecasting
por: Turkulainen, Esa V., et al.
Publicado: (2022)

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib
por: Estupiñán, H. Yesid, et al.
Publicado: (2021)

Predicting vasovagal reactions to a virtual blood donation using facial image analysis
por: Rudokaite, Judita, et al.
Publicado: (2022)

First results of a ferritin‐based blood donor deferral policy in the Netherlands
por: Vinkenoog, Marieke, et al.
Publicado: (2020)

Mitigating the risk of transfusion‐transmitted infections with vector‐borne agents solely by means of pathogen reduction
por: Stramer, Susan L., et al.
Publicado: (2022)

Staff perspectives on barriers and enablers to implementing alternative source plasma eligibility criteria for gay, bisexual, and other men who have sex with men
por: Castillo, Gisell, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1tfcfr1aj5peiejko60hmhdt8d